… MK-0457 is currently undergoing a phase I trial in leukemias, including … the T315I mutation
have been reported.26 A phase II trial in the specific setting of T315I-positive Ph leukemias is …

… relapse in patients with T315I mutation and patients without T315I mutation to observe
the … agents are crucial for leukemia patients with the T315I mutation or other mutations. …

… T315I mutation in BCR-ABL causes resistance to therapy with … positive acute lymphoblastic
leukemia (Ph + ALL) cases. We report three cases of relapse accompanied by T315I mutation …

… CML patients harboring a T315I mutation may have a transient … activity against T315I
mutation-bearing leukemic cells in preclinical … of CML and Ph + ALL patients with T315I mutations. …

… leukemia (CML) with T315I mutation has been reported to have poor prognosis. We analyzed
27 patients with T315I, including 20 who developed T315I … developed new mutations after …

… but is likely to become the prevalent mutation in those who fail to benefit … leukemias that
has been documented to be effective in CML and Ph ALL patients harboring the T315I mutation.…

… dasatinib or nilotinib or who have the T315I mutation. Of 449 patients enrolled in … T315I
mutation at enrollment. The EBMT registry collects data on demographics, treatments, mutations, …

… T315I mutation was detected in 4 of the 5 relapsed patients, despite the absence of BCR-ABL
mutations … significantly lower in patients with T315I than those without the mutation (C 2h , …

… /ABL and BCR/ABL–T315I that also inhibits all known BCR/ABL mutants in vitro, as well …
T315I mutation. As a multikinase inhibitor, ponatinib also targets kinases implicated in mutation-…

… 0457 to avoid the steric constraints imposed by the T315I mutations (39). In a recent phase
I study that included 9 patients with BCR-ABL1 T315I-positive refractory CML in either AP (n = …